Melanie Carreon, M.D., P.A
EMR-Friendly & Ready to Use Delivered as an easy-to-upload PDF you can share digitally with clients or print for in-session use
References: [1] The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease [2] [3] Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial [4] STEP-HFpEF: Semaglutide Improves Symptoms, Physical Limitations, Weight Loss in Patients With HFpEF and Obesity
Always consult a qualified, licensed healthcare professional before making any decision related to your health.
dulaglutide or oral semaglutide for the treatment of type 2 diabetes is considered not to be cost-effective
Consistent Daily Performance: The protected structure helps deliver reliable support each day, even with regular long-term use